1. Generics Bulletin

Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines

Reference Product Sales More Than $16bn In 2021

 
• By Rosalind Rei

Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules. 

Pile of pills, with one pill bearing the flag of the Philippines
The biosimilars named under the deal reference top-selling global drugs • Source: Shutterstock

Lupin Limited has signed an exclusive license and supply agreement with DKSH to commercialize five of Alvotech’s proposed biosimilars in the Philippines.

Approval filing, distribution, and commercialization will fall to Lupin’s subsidiary in the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business